I. Oiartzabal

发表

Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.

J. Esteve, E. Campo, F. Solé, 2017, Leukemia research.

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice

M. Tormo, S. Brunet, J. Bargay, 2022, Leukemia & lymphoma.

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

M. Tormo, M. Calasanz, C. Solano, 2021, British journal of haematology.

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

F. Prósper, B. Paiva, J. San-Miguel, 2021, Blood Cancer Journal.

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

J. Esteve, M. Cazzola, R. Schlenk, 2020, Leukemia.

Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale.

E. González-Barca, Mar Durán, S. Bonanad, 2015, Journal of geriatric oncology.

Assessment of the introduction of a blood management program in orthopaedic surgery

A. López-Picado, I. Oiartzabal, J. Molano, 2015 .

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

M. Tormo, M. Calasanz, C. Solano, 2020, Blood.

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

J. Hernández-Rivas, L. Villalón, J. Ribera, 2023, European journal of haematology.